ARVN Arvinas, Inc. Stock Quote

ARVN [NASD]

Index	-	P/E	-	EPS (ttm)	-3.00	Insider Own	9.60%	Shs Outstand	41.78M	Perf Week	1.89%
Market Cap	3.21B	Forward P/E	-	EPS next Y	-4.07	Insider Trans	0.19%	Shs Float	41.19M	Perf Month	-10.53%
Income	-119.30M	PEG	-	EPS next Q	-0.81	Inst Own	96.00%	Short Float	4.62%	Perf Quarter	-26.25%
Sales	21.80M	P/S	147.18	EPS this Y	-41.40%	Inst Trans	26.34%	Short Ratio	4.24	Perf Half Y	156.60%
Book/sh	15.37	P/B	4.21	EPS next Y	-16.60%	ROA	-31.10%	Target Price	109.09	Perf Year	32.02%
Cash/sh	13.88	P/C	4.66	EPS next 5Y	-	ROE	-38.00%	52W Range	19.68 - 92.77	Perf YTD	-23.83%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-30.27%	Beta	-
Dividend %	-	Quick Ratio	14.30	Sales past 5Y	-	Gross Margin	-	52W Low	228.71%	ATR	4.03
Employees	179	Current Ratio	14.30	Sales Q/Q	-55.10%	Oper. Margin	-	RSI (14)	46.92	Volatility	6.10% 6.69%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-70.50%	Profit Margin	-	Rel Volume	1.16	Prev Close	63.00
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	449.43K	Price	64.69
Recom	1.60	SMA20	1.71%	SMA50	-9.79%	SMA200	37.65%	Volume	519,510	Change	2.68%

Mar-31-21

Initiated

BMO Capital Markets

Outperform

$101

Dec-14-20

Upgrade

Oppenheimer

Perform → Outperform

Jun-01-20

Upgrade

Citigroup

Neutral → Buy

$45

May-12-20

Initiated

Oppenheimer

Perform

Dec-19-19

Initiated

H.C. Wainwright

Buy

$50

Nov-25-19

Initiated

Guggenheim

Buy

$50

Oct-24-19

Upgrade

Goldman

Neutral → Buy

$23 → $38

Sep-25-19

Initiated

Wedbush

Outperform

$38

Sep-12-19

Initiated

BMO Capital Markets

Outperform

Aug-06-19

Initiated

Cantor Fitzgerald

Overweight

$42

Jun-05-19

Downgrade

Citigroup

Buy → Neutral

$21 → $22

Apr-12-19

Initiated

Evercore ISI

Outperform

Oct-22-18

Initiated

Piper Jaffray

Overweight

$23

Oct-22-18

Initiated

Goldman

Neutral

$17

Oct-22-18

Initiated

Citigroup

Buy

$21

Apr-12-21 02:28PM	Is ARVN Stock A Buy or Sell? Insider Monkey
Apr-05-21 04:30PM	Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021 GlobeNewswire
Mar-10-21 04:30PM	Arvinas to Participate in Upcoming Virtual Investor Conferences GlobeNewswire
Mar-01-21 08:15AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates Zacks
07:59AM	Arvinas: Q4 Earnings Insights Benzinga
07:00AM	Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update GlobeNewswire
Feb-18-21 12:01AM	What Kind Of Shareholders Hold The Majority In Arvinas, Inc.'s (NASDAQ:ARVN) Shares? Simply Wall St.
Feb-08-21 04:30PM	Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day GlobeNewswire
Dec-28-20 04:30PM	Arvinas, Inc. Announces Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Dec-23-20 04:40PM	3 Strong Buy Stocks Insiders Are Snapping Up TipRanks
Dec-16-20 01:37PM	Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More Zacks -10.51%
Dec-15-20 08:35PM	Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock GlobeNewswire +27.18%
07:48PM	Arvinas Cancer Drug Has Blockbuster Potential, Says Analyst TipRanks
09:48AM	ROCE Insights For Arvinas Benzinga
09:17AM	Arvinas (ARVN) Up on Promising Interim Data on Cancer Candidates Zacks
Dec-14-20 04:37PM	Why This Small Biotech Stock Nearly Doubled In Bullish Volume Investor's Business Daily +95.06%
04:06PM	Arvinas, Inc. Announces Proposed Offering of Common Stock GlobeNewswire
01:50PM	Arvinas Nearly Doubles on Promising Cancer Drug Results TheStreet.com
09:48AM	Return On Capital Employed Overview: Arvinas Benzinga
07:00AM	Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110 GlobeNewswire
Dec-11-20 04:15PM	Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs GlobeNewswire
Nov-25-20 07:00AM	Arvinas to Participate in Upcoming Virtual Investor Conferences GlobeNewswire
Nov-16-20 09:21AM	New Strong Sell Stocks for November 16th Zacks
Nov-07-20 07:43AM	Arvinas, Inc. (NASDAQ:ARVN) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year Simply Wall St.
Nov-05-20 07:00AM	Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
05:52AM	Rock star Growth Puts Arvinas (NASDAQ:ARVN) In A Position To Use Debt Simply Wall St.
Oct-14-20 07:00AM	Arvinas Announces Pipeline Programs Targeting Validated and Classically Undruggable Disease-Causing Proteins GlobeNewswire
Oct-06-20 05:17PM	Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit GlobeNewswire
Sep-15-20 11:42AM	Hedge Funds Have Never Been This Bullish On Arvinas, Inc. (ARVN) Insider Monkey
Sep-04-20 07:00AM	Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference GlobeNewswire
Aug-07-20 07:00AM	Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference GlobeNewswire
Aug-04-20 09:05AM	Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates Zacks -5.67%
07:00AM	Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Jul-30-20 08:45AM	The Arvinas (NASDAQ:ARVN) Share Price Has Gained 30% And Shareholders Are Hoping For More Simply Wall St.
Jul-27-20 12:31PM	Earnings Preview: Arvinas, Inc. (ARVN) Q2 Earnings Expected to Decline Zacks
Jul-20-20 12:15PM	Did Hedge Funds Make The Right Call On Arvinas, Inc. (ARVN) ? Insider Monkey
Jun-29-20 04:30PM	Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors GlobeNewswire
Jun-17-20 07:00AM	Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-15-20 09:48AM	Here is What Hedge Funds Think About Arvinas, Inc. (ARVN) Insider Monkey
Jun-11-20 07:00AM	Arvinas Appoints Linda Bain to its Board of Directors GlobeNewswire -5.26%
Jun-05-20 12:00PM	Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why Zacks +8.21%
07:00AM	Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference GlobeNewswire
May-29-20 10:28AM	P/E Ratio Insights for Arvinas Benzinga -25.82%
07:00AM	Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer GlobeNewswire
May-20-20 04:30PM	Arvinas to Hold Virtual 2020 Annual Meeting of Stockholders GlobeNewswire
May-14-20 12:33PM	Here's Why Arvinas Shares Are Tumbling 13.7% Today Motley Fool -13.35%
May-13-20 05:49PM	Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer GlobeNewswire -8.52%
May-12-20 08:54AM	How Arvinas (ARVN) Stock Stands Out in a Strong Industry Zacks
May-05-20 12:00PM	Arvinas, Inc. (ARVN) Upgraded to Buy: Here's What You Should Know Zacks
May-01-20 06:33AM	Analysts Are Upgrading Arvinas, Inc. (NASDAQ:ARVN) After Its Latest Results Simply Wall St.
Apr-28-20 09:37AM	Recap: Arvinas Q1 Earnings Benzinga
08:35AM	Arvinas, Inc. (ARVN) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:00AM	Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update GlobeNewswire
Apr-18-20 10:02AM	Were Hedge Funds Right About Arvinas, Inc. (ARVN)? Insider Monkey
Apr-13-20 04:54PM	Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic GlobeNewswire
Mar-31-20 07:00AM	Arvinas to Present at the American Society of Clinical Oncology Annual Meeting GlobeNewswire
06:27AM	The Arvinas, Inc. (NASDAQ:ARVN) Analysts Have Been Trimming Their Sales Forecasts Simply Wall St.
Mar-20-20 11:30AM	Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year? Zacks
Mar-19-20 08:56AM	Why You Shouldn't Bet Against Arvinas (ARVN) Stock Zacks +8.60%
Mar-18-20 06:52AM	Is Arvinas (NASDAQ:ARVN) A Risky Investment? Simply Wall St.
Mar-16-20 08:15AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates Zacks -18.40%
07:00AM	Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
Feb-17-20 12:00PM	Arvinas, Inc. (ARVN) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Jan-31-20 09:31AM	What's in the Offing for Emerson (EMR) in Q1 Earnings? Zacks
Jan-29-20 06:51AM	Will Arvinas Continue to Surge Higher? Zacks
Jan-17-20 05:37AM	Shareholders Are Thrilled That The Arvinas (NASDAQ:ARVN) Share Price Increased 208% Simply Wall St.
Dec-19-19 06:27PM	Did Hedge Funds Drop The Ball On Arvinas, Inc. (NASDAQ:ARVN) ? Insider Monkey
Nov-27-19 07:30AM	Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire +8.63%
Nov-26-19 08:06AM	The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug Benzinga
Nov-25-19 11:40AM	Arvinas TPD Therapies Have Great Potential, Guggenheim Says In Bullish Initiation Benzinga
Nov-21-19 07:30AM	Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors GlobeNewswire
Nov-17-19 12:44PM	Notable Insider Buys In The Past Week: Arvinas, Dropbox, Trinity Benzinga
Nov-06-19 09:40PM	Arvinas, Inc. Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:01PM	Arvinas, Inc. Announces Proposed Offering of Common Stock GlobeNewswire
Nov-05-19 09:00AM	Arvinas, Inc. (ARVN) Upgraded to Strong Buy: Here's Why Zacks +5.11%
Nov-04-19 05:00PM	Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Oct-31-19 11:50AM	Goldman Sachs: 3 Standout Healthcare Stocks That Could Double TipRanks
Oct-30-19 09:36AM	Hedge Funds Are Selling Arvinas, Inc. (ARVN) Insider Monkey
Oct-23-19 07:54AM	The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data Benzinga +14.64%
06:30AM	Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders GlobeNewswire
Oct-20-19 08:08AM	The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict Benzinga
Oct-19-19 09:02AM	Have Insiders Been Buying Arvinas, Inc. (NASDAQ:ARVN) Shares This Year? Simply Wall St.
Oct-17-19 07:00AM	Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit GlobeNewswire
Oct-02-19 07:00AM	Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders GlobeNewswire
Oct-01-19 02:54PM	Bayer funnels $55M into new startup with Triangle touchpoint American City Business Journals -7.10%
04:00AM	Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio GlobeNewswire
Sep-25-19 02:44PM	Wedbush Starts Arvinas At Outperform, Says Lead Assets Could Have Successful Trials Benzinga
Aug-27-19 07:00AM	Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader GlobeNewswire
Aug-16-19 12:46PM	David Swensen Sells DocuSign in 2nd Quarter GuruFocus.com
Aug-07-19 07:00AM	Arvinas To Present at the Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-05-19 07:00AM	Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire -7.86%
Jul-31-19 01:48PM	Steven Cohen Charges Into Chiasma GuruFocus.com
Jul-29-19 07:00AM	Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer GlobeNewswire
Jul-25-19 07:00AM	Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk GlobeNewswire +7.28%
Jul-18-19 07:00AM	Arvinas to Present Preclinical Tau-Directed PROTAC® Protein Degrader Data at Alzheimer's Association International Conference GlobeNewswire
Jun-27-19 06:54AM	Will Arvinas Continue to Surge Higher? Zacks
Jun-26-19 06:28PM	Is Arvinas, Inc. (ARVN) A Good Stock To Buy? Insider Monkey
Jun-25-19 07:00AM	Arvinas Receives Authorization to Proceed for ARV-471, a PROTAC® Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer GlobeNewswire
Jun-20-19 08:30AM	Arvinas to Present at the BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-06-19 07:00AM	Arvinas to Present at the Goldman Sachs 40th Annual Global Healthcare Conference GlobeNewswire

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Taylor Ian	Chief Scientific Officer	Apr 05	Option Exercise	16.00	25,000	400,000	103,645	Apr 07 06:00 PM
Taylor Ian	Chief Scientific Officer	Apr 05	Sale	66.81	25,000	1,670,143	78,645	Apr 07 06:00 PM
Taylor Ian	Chief Scientific Officer	Mar 02	Sale	77.45	894	69,240	78,645	Mar 02 09:04 PM
Cassidy Sean A	Chief Financial Officer	Mar 02	Sale	77.45	2,221	172,015	158,249	Mar 02 09:02 PM
Houston John G	President and CEO	Mar 02	Sale	77.45	8,115	628,503	827,643	Mar 02 09:00 PM
Taylor Ian	Chief Scientific Officer	Feb 19	Option Exercise	16.00	6,456	103,296	76,854	Feb 23 06:09 PM
Cassidy Sean A	Chief Financial Officer	Feb 17	Option Exercise	16.00	894	14,304	155,678	Feb 18 05:16 PM
Houston John G	President and CEO	Feb 16	Option Exercise	16.00	1,560	24,960	817,760	Feb 18 05:26 PM
Peck Ronald	Chief Medical Officer	Feb 16	Option Exercise	26.58	20,000	531,600	22,754	Feb 18 05:05 PM
Cassidy Sean A	Chief Financial Officer	Feb 16	Option Exercise	16.00	41,959	671,344	196,743	Feb 18 05:09 PM
Houston John G	President and CEO	Feb 16	Option Exercise	16.00	44,000	704,000	860,000	Feb 18 05:11 PM
Houston John G	President and CEO	Feb 16	Sale	78.79	44,000	3,466,601	816,200	Feb 18 05:11 PM
Cassidy Sean A	Chief Financial Officer	Feb 16	Sale	78.46	41,959	3,292,108	154,784	Feb 18 05:09 PM
Peck Ronald	Chief Medical Officer	Feb 16	Sale	77.35	20,000	1,546,992	2,754	Feb 18 05:05 PM
Ratcliffe Liam	Director	Dec 18	Buy	70.00	142,857	9,999,990	822,857	Dec 21 06:00 PM
Cassidy Sean A	Chief Financial Officer	Nov 09	Option Exercise	16.00	3,006	48,096	154,784	Nov 12 06:00 PM
Kennedy Edward Moore Jr.	Director	Nov 09	Buy	23.99	8,333	199,909	42,718	Nov 12 06:05 PM
Peck Ronald	Chief Medical Officer	Aug 14	Sale	27.46	1,256	34,490	2,754	Aug 18 07:00 PM
SHANNON TIMOTHY M	Director	Jun 17	Buy	30.26	2,000	60,520	79,546	Jun 19 05:00 PM
SHANNON TIMOTHY M	Director	Jun 02	Buy	32.30	3,000	96,900	77,546	Jun 04 09:00 PM
SHANNON TIMOTHY M	Director	May 26	Option Exercise	22.06	12,923	285,081	74,546	May 26 07:05 PM
Ratcliffe Liam	Director	May 26	Option Exercise	22.06	6,500	143,390	6,500	May 27 06:34 PM
Cassidy Sean A	Chief Financial Officer	May 13	Option Exercise	16.00	1,356	21,696	151,778	May 14 09:30 PM
Cassidy Sean A	Chief Financial Officer	May 12	Sale	60.00	10,000	600,000	150,422	May 14 09:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience